BAMCO, Inc. - Baron Emerging Markets Fund on Acutaas Chemicals Limited
Thesis
Acutaas is an Indian manufacturer of advanced pharmaceutical intermediates and specialty chemicals with high market share in several critical products. Its R&D pipeline, higher-margin CDMO expansion and long-term darolutamide contract provide multiple growth drivers. Baron expects compound revenue and earnings growth above 20% over the next three to five years.
“the company is well positioned to deliver compound revenue and earnings growth in excess of 20% over the next three to five years.”